United States Patent 5,508,020: Scope, Claim Structure, and Landscape for Tc-99m Scintigraphic Imaging Agents
What does US 5,508,020 claim in plain technical terms?
US 5,508,020 is directed to composition-of-matter reagents used to prepare scintigraphic imaging agents for mammalian imaging sites. The core claim construction is a multi-functional conjugate that combines:
- A multiplicity of specific-binding peptides (3 to 100 amino acids each) that bind a target site in a mammal
- A polyvalent linking moiety covalently linking the peptide(s)
- A technetium-99m (Tc-99m) binding moiety covalently linked either:
- to the peptide(s), or
- to the polyvalent linker, or
- both
- The reagent is a member of a defined set of chemical formulas (the claim text you provided references STR8/STR9/STR10)
The claims as presented are formula-driven composition claims plus a broader functional composition claim.
Claim set as provided
- Claim 1: Broad composition-of-matter definition for a reagent selected from a group of “reagents having the formula” (STR8).
- Claim 2: A specific composition of matter defined by formula STR9.
- Claim 3: Another specific composition of matter defined by formula STR10.
How is Claim 1 scoped, and what must an accused product contain?
Claim 1 is structured as an “A composition of matter comprising” claim. Infringement risk turns on whether the accused composition satisfies each mandatory element:
1) “Reagent for preparing a scintigraphic imaging agent”
- The claim requires the composition itself be a reagent used to prepare a scintigraphic imaging agent.
- This is a functional tie to downstream use, but because it is a composition-of-matter claim, the reagent’s chemical structure must support Tc-99m binding and target binding.
2) “Multiplicity of specific-binding peptides”
- The composition must have more than one peptide (multiplicity).
- Each peptide must:
- be 3 to 100 amino acids
- specifically bind to a site in a mammalian body
3) Covalent architecture: peptide + polyvalent linker + Tc-99m binder
Claim 1 specifies a covalent arrangement:
- Each peptide is covalently linked to a polyvalent linking moiety, OR the polyvalency allows multiple peptide attachments through that linker.
- A Tc-99m binding moiety is covalently linked to:
- a plurality of peptides, or
- the polyvalent linker moiety, or
- both
This yields a modular conjugate where Tc coordination chemistry is built into the conjugate scaffold rather than relying on noncovalent association.
4) Selection limitation: “selected from reagents having the formula”
Claim 1 is limited to a defined set of chemical reagents by formula group membership (STR8 referenced in your excerpt).
- This is critical: even if a conjugate contains peptides + polyvalent linker + Tc-99m binding moiety, it still needs to fall within the formula-defined group.
5) What the formula limitation changes in practice
For landscape analysis, the formula limitation typically narrows the scope to particular:
- linker backbones
- functional groups that carry peptides and Tc-99m chelation chemistry
- presence/absence of specific spacer/linker moieties and chelator chemistry
Because the formulas are not reproduced in your excerpt (only STR8/STR9/STR10 placeholders), the analysis below focuses on the structural claim logic you provided, and the standard way courts assess formula claims: the accused structure must match the claimed structural variables.
What does Claims 2 and 3 narrow to?
Claims 2 and 3 are narrower species claims, each defined by a specific chemical formula:
- Claim 2: “A composition of matter having the formula: ##STR9##”
- Claim 3: “A composition of matter having the formula: ##STR10##”
Practical inference from species claim construction
Even without the actual STR images rendered, the legal effect is clear:
- Claim 1 covers a class defined by a formula group (STR8).
- Claims 2 and 3 cover particular embodiments inside that class (STR9 and STR10).
So the patent landscape relevance is:
- competitors may try to design around by altering the chelator or linker chemistry so they fall outside STR8 while still achieving Tc labeling and peptide targeting.
- the main freedom-to-operate question becomes whether an accused conjugate matches the exact formula-defined class boundaries, not just whether it works as a Tc-99m imaging agent.
What is the technical “design space” the patent occupies?
The claim describes a conjugate platform that merges:
- targeting: peptide-based binding ligands (3 to 100 aa)
- multivalency: multiple peptide binding units per construct
- radiolabeling: covalently tethered Tc-99m binding moiety
Claim-relevant design variables
The scope hinges on these variables:
-
Peptide length and binding specificity
- 3 to 100 aa per peptide
- “specific-binding” to a mammalian site
-
Multivalency
- “multiplicity” implies multiple peptide units attached through a “polyvalent linking moiety.”
-
Tc-99m chelator placement
- Tc binding moiety attached to:
- peptides, or
- polyvalent linker, or
- both
-
Chemical formula class (STR8)
- This is the tightest scoping mechanism.
- It constrains which chelator/linker backbones qualify.
How does this map into a typical Tc-99m peptide imaging competitor strategy?
In the Tc-99m peptide imaging space, competitors generally choose among:
- single-chelator vs multivalent constructs
- chelator type and attachment site (peptide vs scaffold)
- linker chemistry (polyvalent scaffolds vs monovalent spacers)
US 5,508,020 claims the multivalent-peptide + covalent Tc-chelator conjugate architecture, but it does not read as “any Tc-99m peptide conjugate.” It reads as Tc-99m-conjugated multipeptide constructs within the claimed chemical formula group.
That means a design-around strategy usually targets either:
- the scaffold to move outside the STR8 formula group, or
- the linkage strategy so Tc-chelation moiety is not covalently arranged in the claimed way, or
- the multivalency pattern so the construction does not meet “multiplicity of specific-binding peptides” as structurally claimed.
What is the likely independent claim breadth and invalidity pressure profile?
Based on claim structure, US 5,508,020 has two core breadth levers and two constraining levers.
Breadth levers
- Wide peptide domain: any specific-binding peptide of 3 to 100 aa
- Wide binding target domain: “a site in a mammalian body” (no specific receptor/site limitation stated in Claim 1 excerpt)
Constraining levers
- Structural formula membership via STR8
- Covalent architecture requirements: peptide-linker-Tc linkage scheme
Landscape implication
The claim’s enforceability against modern entrants often depends on whether they still use the same or closely related:
- multivalent linking scaffolds
- Tc-99m chelator chemistries
- covalent attachment logic that falls inside STR8
Without the actual STR chemical structures reproduced, a full element-by-element comparison to specific modern products cannot be completed from the provided excerpt alone.
Where does US 5,508,020 sit in the broader patent landscape for Tc-99m peptide imaging?
US 5,508,020 fits within a radiopharmaceutical IP pattern:
- Targeting ligand (peptides)
- Multivalent display (polyvalent linker + multiple peptide units)
- Radiolabeling handle (Tc-99m-binding moiety covalently integrated)
In practice, patent landscapes for Tc-99m peptide imaging usually fragment into overlapping layers:
- chelator chemistry patents (Tc-binding moieties)
- peptide targeting patents (specific peptide sequences and binding)
- multivalent scaffold patents (linker architecture, conjugation handles)
- labeling chemistry and kit/regimen patents (labeling methods and conditions)
- imaging agent formulations (pharmaceutical compositions)
US 5,508,020 is primarily a composition platform patent aimed at the conjugate itself, rather than a specific peptide sequence or a specific imaging protocol.
What claims are most relevant for enforcement vs licensing?
Highest relevance: Claim 1
Claim 1 is the broad umbrella because it defines:
- the conjugate composition class (subject to STR8 formula group)
- the required structural relationships (peptide multivalency + polyvalent linker + Tc covalent binding)
Secondary relevance: Claims 2 and 3
Claims 2 and 3 cover defined species (STR9 and STR10). These often matter because:
- they can anchor licensing deals even if the broad class is contested
- they can support narrower design-around avoidance if products map to one of the species embodiments
What does the landscape look like by claim-family risk (practical mapping)?
Because the excerpt does not provide:
- the publication number(s),
- prosecution history,
- explicit claims beyond 1-3,
- or the content of STR8/STR9/STR10 chemical drawings,
a complete freedom-to-operate analysis across named competitors cannot be reliably produced from the data provided.
However, the risk model for any competitor product can be stated precisely at the claim-logic level:
Product-to-claim match checklist
An accused composition is most likely to fall within scope if it has all of the following:
- multivalent peptide targeting units
- peptides in the 3 to 100 aa range
- peptides covalently linked to a polyvalent linker
- Tc-99m binding moiety covalently linked to:
- the peptides and/or
- the polyvalent linker
- the overall conjugate structure conforms to the STR8 chemical formula group (Claim 1)
Where competitors typically carve out
- Use a different chelator chemistry or scaffold that changes the formula variables beyond STR8 boundaries.
- Use a noncovalent Tc association (less common for modern covalent Tc agents, but still possible in certain labeled preparations).
- Use monovalent or differently valenced constructs that may not satisfy the “multiplicity” structural relationship required by the formula.
What is the legal “shape” of this patent: composition of matter only?
From the claim text you provided, the patent is at minimum composition-of-matter.
- It claims reagents that are chemical conjugates.
- There is no expressed method claim in your excerpt.
- That matters for infringement: purchasers, manufacturers, and label kit users can be implicated depending on how the composition is sold and used, but the core claim coverage is the composition structure.
Key Takeaways
- US 5,508,020 covers Tc-99m radiolabelable, multivalent peptide conjugate reagents where peptides (3 to 100 aa) are covalently linked to a polyvalent linker, and a Tc-99m binding moiety is covalently linked to the peptides and/or the linker.
- Claim 1 is broad on peptide and target identity but narrow on chemical structure through a formula-defined group (STR8).
- Claims 2 and 3 are narrower species defined by additional formulas (STR9 and STR10).
- The competitive risk for modern products is primarily determined by whether their conjugate chemistry matches the STR8/STR9/STR10 structural formula boundaries, not by functional imaging performance alone.
FAQs
1) Is US 5,508,020 limited to specific peptide sequences?
Claim 1 as provided is not sequence-specific; it requires “multiplicity of specific-binding peptides” each 3 to 100 amino acids that specifically bind a mammalian site. The limiting factor is the chemical formula group (STR8), not a named peptide sequence.
2) Where can the Tc-99m binding moiety be attached under Claim 1?
It can be covalently linked to a plurality of the peptides, to the polyvalent linker moiety, or to both.
3) Does “selected from the group consisting of reagents having the formula” narrow Claim 1 materially?
Yes. It turns Claim 1 into a structural class claim bounded by the formula group (STR8). Conjugates outside the formula-defined boundaries are not covered even if they perform Tc-99m peptide imaging.
4) Are Claims 2 and 3 broader than Claim 1?
No. They are narrower because each is defined by a specific chemical formula (STR9 and STR10), which are embodiments within the broader STR8-defined class.
5) Is this patent primarily about a method or a composition?
The claims you provided are composition-of-matter (reagents/conjugates) rather than methods.
References
[1] United States Patent 5,508,020. (n.d.). Composition of matter for Tc-99m scintigraphic imaging agents. (Claims 1-3 as provided in the user prompt excerpt).
